Explore tweets tagged as #CheckMate274
Latest Update on CheckMate 274: Adjuvant Nivolumab in High-Risk MIUC. #UrothelialCancer #Immunotherapy #Oncology #Nivolumab #BladderCancer #CheckMate274 #CancerResearch.
0
0
0
Adjuvant nivolumab vs placebo for high-risk muscle-invasive #UrothelialCarcinoma: Additional efficacy outcomes including overall survival in patients with #MIBC from #CheckMate274. Presentation by @MattMilowsky @UNC_Lineberger. #GU25 written coverage by @zklaassen_md
0
13
28
At @ASCO - #GU25, Dr. @sonpavde highlights the CheckMate 274 trial while talking to @brunolarvol in a Quick Takes session. #LARVOL #GUCancer #CheckMate274 #Oncology #CancerResearch #GenitourinaryCancer
0
4
8
@ERPlimackMD with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ASCO #GU25
0
3
9
@MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing @ALLIANCE_org #MODERN trial! @ASCO #GU25
0
4
8
Neues aus der Urologie: oncologics präsentiert den aktuellen Forschungsstand anhand einschlägiger Studien, präsentiert durch unsere Expertinnen und Experten in anschaulichen Kurzvideos. Behandelt werden unter anderem die #PREVAIL, die #CheckMate274, die #IMvigor211, die
0
0
0
Muskelinvasives Blasenkarzinom: ctDNA nach Zystektomie zeigt zuverlässig Rezidivrisiko an: Barcelona – Das muskelinvasive Harnblasenkarzinom wird in der Regel neoadjuvant behandelt und danach radikal operiert. Nur bei… #ESMO2024 #NEJM #CheckMate274
0
0
1
@GUOncologyNow @sonpavde The emerging insights from @sonpavde on perioperative #PDL1 therapy for advanced #BladderCancer in trials like #CheckMate274, #AMBASSADOR, and #NIAGRA are compelling. How do these findings shape current therapeutic strategies? Have you seen significant differences in patient.
0
0
1
🎥 Don't miss @sonpavde's thoughts on first-line #perioperative #PDL1 therapy for advanced #BladderCancer, including the #CheckMate274, #AMBASSADOR, and #NIAGRA trials. 👀 Watch Here:
1
1
6
🎥 Don't miss @sonpavde's thoughts on first-line #perioperative #PDL1 therapy for advanced #BladderCancer, including the #CheckMate274, #AMBASSADOR, and #NIAGRA trials. 👀 Watch Here:
0
0
3
Dr @DiMariaJiang discusses results of the #CheckMate274 study on patients with muscle-invasive #urothelialcarcinoma. See her full analysis here: . Watch all content from our Best of ASCO®️ GU & GI Cancers conference here: . #MedOnc
0
1
3
🎙️ In episode 309 of the @Uromigos, @brian_rini and @tompowles1 talk with @MattGalsky about the #OS signal data from #CheckMate274, which analyzed the use of #adjuvant #nivolumab in patients with #MIBC. 👉 Listen Here:
0
1
7
🎙️ @brian_rini and @tompowles1 of the @Uromigos spoke with @MattGalsky about the #OS signal data from #CheckMate274, which analyzed the use of #adjuvant #nivolumab in patients with #MIBC. 👂 Listen Here:
0
2
4
#EAU24 #checkmate274 +ve DFS early +ve OS #IM010 -ve for both. #AMBASSADOR +ve DFS early -ve OS. Perhaps too early. How do we explain. Subsequent therapy hard to read. dynamic. Maybe ctDNA+ trials will have clearer signals from more likely events.
1
10
26
@urotoday @MattGalsky @TischCancer @zklaassen_md @GACancerCenter @Uroweb The extended follow-up insights from #CheckMate274, especially with the inclusion of overall survival outcomes, are indeed pivotal in understanding the efficacy and longevity of treatments within urologic oncology. It's encouraging to see comprehensive coverage and dissemination.
0
0
0
Extended follow-up from #CheckMate274 including the first report of overall survival outcomes. Presentation by @MattGalsky @TischCancer. #EAU24 written coverage by @zklaassen_md @GACancerCenter on UroToday > @Uroweb
1
4
7